Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of MVP used as antiviral drug target

An antiviral drug and virus technology, applied in the field of medicine, can solve the problems of insufficient dosage, reduced curative effect, toxic and side effects, etc., and achieve the effects of reducing liver tissue lesions, inhibiting virus replication, and improving liver function

Inactive Publication Date: 2012-06-27
WUHAN UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, there is a contradiction between the dosage and the curative effect of the widely used polyethylene glycol IFN combined with ribavirin in the treatment of chronic hepatitis C. : Insufficient dosage will cause the reduction of curative effect, and higher dosage will cause certain toxic and side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of MVP used as antiviral drug target
  • Application of MVP used as antiviral drug target
  • Application of MVP used as antiviral drug target

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0037] MVP is used to inhibit the replication of viruses such as hepatitis C by inducing the production of type I IFN, thereby exerting antiviral applications.

[0038] 1. Effect of MVP on virus replication

[0039] 1. Materials: cells, viruses and plasmids

[0040] MDCK cells were provided by Shandong Institute of Medical Microbiology, Chinese Academy of Sciences, and Huh7 cells, Huh7.5.1 cells, RD cells, and Vero cells were all purchased from China Collection Center for Typical Microorganisms;

[0041] HCV JFH-1, H3N2, VSV, EV71 were purchased from China Collection Center for Typical Microorganisms;

[0042] The pCMV-MVP and sh-MVP plasmids were completed under the guidance of Professor Zhu Ying from the Medical Virology Research Group of the State Key Laboratory of Virology, Wuhan University;

[0043] 2. Tool enzyme

[0044] LA-taq, LC-taq, M-MLV reverse transcriptase, 5×M-MLV buffer, RNA exhibit were purchased from TaKara;

[0045] 3. Other reagents

[0046] DMEM po...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of MVP used as an antiviral drug target. The invention verifies that a high expression of MVP can be detected in the hepatic tissue, the blood serum and the human peripheral mononuclear cells separated from the blood of a hepatitis C patient; meanwhile, as shown in an in vitro experiment, the mRNA and protein expression levels of MVP in the cell increase after the hepatitis C virus is infected with Huh7 and Huh7.5.1 cells, and VSV, IAV, and EV71 can induce the MVP expression to inhibit the virus copy so as to realize an antiviral function. As shown in a further mechanism research, the MVP expression increases after the virus stimulates the organism, and the MVP induces the generation of I-type interferon to inhibit the virus copy so as to realize theantiviral function. The application of MVP used as antiviral drug target provided in the invention can be used as a novel drug target to develop medicine for treating hepatitis caused by HCV and diseases caused by other viruses.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of MVP as a target of antiviral drugs. Background technique [0002] In 1989, scientists from the Chiron Corporation of the United States and the Center for Disease Control adopted the molecular biology method of studying nucleic acid first and then protein (antigen), and finally cloned the pathogen of chronic non-A non-B hepatitis. This virus was named C Hepatitis virus (HCV), the hepatitis it causes is called hepatitis C. The World Health Organization report released recently shows that hepatitis C is one of the top ten infectious diseases that cause death in the world. There are currently 40 million HCV-infected people in my country, much higher than the approximately 650,000 HIV-infected and sick people in China, and the chronicity rate of only 5%-10% of adolescents and adults infected with HBV Compared with, about 50%-85% of patients infected wi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/68G01N33/53A61K38/17A61P31/14
Inventor 朱应吴建国彭南方刘实
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com